Tafamidis, Pfizer’s treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), has been granted a priority review designation from the FDA, potentially speeding its path to approval.

Inhibiting a certain class of cyclin-dependent kinase (CDK) proteins could protect cancer patients from chemotherapy-induced heart failure—the second leading cause of death in the demographic after cancer recurrence—according to research published in the Journal of Biological Chemistry.

Cleveland Clinic researchers identified amyloid deposits in 10.2 percent of patients undergoing carpal tunnel release surgery, suggesting biopsies of hand tissue could be an early signal of life-threatening cardiac amyloidosis.

Research presented this week at the European Society of Cardiology Congress in Munich suggests a new treatment may be emerging for transthyretin amyloid cardiomyopathy—a condition previously thought to be rare and untreatable.

SAN FRANCISCO, May 3, 2018 /PRNewswire/ — Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company developing a novel oral therapy to treat transthyretin (TTR) amyloidosis (ATTR), today announced dosing of the first patient in the Phase 2 clinical trial of AG10 in patients with ATTR cardiomyopathy.

Three leading cardiology societies released a consensus statement on Dec. 10 regarding criteria institutions and operators should follow for left atrial appendage occlusion.

Patients with paroxysmal atrial fibrillation (AF) were less likely to receive guideline recommended anticoagulation therapy compared with persistent AF patients. The analysis presented May 8 at the Heart Rhythm Society scientific sessions in Denver included registry data on more than 62,000 patients.